Adjuvant therapy in colon cancer

被引：0

作者：

Schuch, G. ^{[1
]}

Arnold, D. ^{[1
]}

Bokemeyer, C. ^{[1
]}

机构：

[1] Univ Klinikum Hamburg Eppendorf, Hubertuswald Tumorzentrum, Univ Canc Ctr Hamburg, Onkol Hamatol & Knochenmarktransplantat Sekt Pneu, D-20246 Hamburg, Germany

来源：

ONKOLOGE | 2009年 / 15卷 / 12期

关键词：

Colon cancer; Dukes C disease; Adjuvant chemotherapy; FOLFOX; Bevacizumab; PHASE-III TRIAL; COLORECTAL-CANCER; STAGE-II; MICROSATELLITE INSTABILITY; RANDOMIZED-TRIAL; CHEMOTHERAPY; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; SURVIVAL;

D O I：

10.1007/s00761-009-1722-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Colon cancer is one of the leading cancer diseases in the Western world, with most patients having localized tumors upon their initial diagnosis. Adjuvant chemotherapy is clearly recommended for patients with Dukes C disease. In Dukes B colon cancer, chemotherapy has only marginal effects and is therefore not routinely recommended. However, in patients with risk factors such as insufficient lymph node removal, perforation, etc., chemotherapy might have more impact and should be individually discussed with the patient. Routinely, the combination of oxaliplatin plus 5FU/LV (FOLFOX) should be used. Oral fluoropyrimidines may be given alternatively. Recent results questioned the benefit of adjuvant chemotherapy in elderly patients. Data on bevacizumab combined with FOLFOX did not meet the expectations and will be discussed in detail.

引用

页码：1215 / +

页数：6

共 37 条

[1] Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Colangelo, Linda H. ;

Lopa, Samia H. ;

Petrelli, Nicholas J. ;

Goldberg, Richard M. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) :3385-3390

[2] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer [J].

Andre, T ;

Boni, C ;

Mounedji-Boudiaf, L ;

Navarro, M ;

Tabernero, J ;

Hickish, T ;

Topham, C ;

Zaninelli, M ;

Clingan, P ;

Bridgewater, J ;

Tabah-Fisch, I ;

de Gramont, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2343-2351

[3] Improved Overall Survival With Oxaliplatin, Fluorouracil, and Leucovorin As Adjuvant Treatment in Stage II or III Colon Cancer in the MOSAIC Trial [J].

Andre, Thierry ;

Boni, Corrado ;

Navarro, Matilde ;

Tabernero, Josep ;

Hickish, Tamas ;

Topham, Clare ;

Bonetti, Andrea ;

Clingan, Philip ;

Bridgewater, John ;

Rivera, Fernando ;

de Gramont, Aimery .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (19) :3109-3116

[4]

[Anonymous], J CLIN ONCOL

[5] Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion [J].

Arkenau, HT ;

Rettig, K ;

Porschen, R .

INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2005, 20 (03) :258-261

[6]

BAYRAKTAR UD, 2009, J CLIN ONCOL S, V27, pS15

[7] American society of clinical oncology recommendations on adjuvant chemotherapy for stage II colon cancer [J].

Benson, AB ;

Schrag, D ;

Somerfield, MR ;

Cohen, AM ;

Figueredo, AT ;

Flynn, PJ ;

Krzyzanowska, MK ;

Maroun, J ;

McAllister, P ;

Van Cutsem, E ;

Brouwers, M ;

Charette, M ;

Haller, DG .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3408-3419

[8] Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon Cancer: Cancer and Leukemia Group B Protocol 89803 [J].

Bertagnolli, Monica M. ;

Niedzwiecki, Donna ;

Compton, Carolyn C. ;

Hahn, Hejin P. ;

Hall, Margaret ;

Damas, Beatrice ;

Jewell, Scott D. ;

Mayer, Robert J. ;

Goldberg, Richard M. ;

Saltz, Leonard B. ;

Warren, Robert S. ;

Redston, Mark .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) :1814-1821

[9] Lymph node evaluation and survival after curative resection of colon cancer: Systematic review [J].

Chang, George J. ;

Rodriguez-Bigas, Miguel A. ;

Skibber, John M. ;

Moyer, Virginia A. .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (06) :433-441

[10] A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer [J].

Chau, I ;

Norman, AR ;

Cunningham, D ;

Tait, D ;

Ross, PJ ;

Iveson, T ;

Hill, M ;

Hickish, T ;

Lofts, F ;

Jodrell, D ;

Webb, A ;

Oates, JR .

ANNALS OF ONCOLOGY, 2005, 16 (04) :549-557

← 1 2 3 4 →